Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's) (PRoBaND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02881099|
Recruitment Status : Unknown
Verified April 2020 by Dr Donald Grosset, NHS Greater Glasgow and Clyde.
Recruitment status was: Active, not recruiting
First Posted : August 26, 2016
Last Update Posted : April 17, 2020
|Condition or disease|
To identify genetic and biomarker factors which affect the expression of Parkinson's Disease.
Primary objective: To define the severity and rates of progression of clinical features of Parkinson's Disease.
Secondary objective: To relate clinical phenomenology of Parkinson's disease to genetic and biomarker changes.
|Study Type :||Observational|
|Actual Enrollment :||2614 participants|
|Official Title:||Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||December 23, 2021|
|Estimated Study Completion Date :||June 1, 2022|
Recent diagnosis (P3)
Primary cohort; participants recruited if diagnosed within the last three years
Early diagnosis (P50)
Participants recruited if diagnosed before the age of 50 years old
Siblings of existing participants
- Proportion of participants with Parkinson's who have gene mutations and variations [ Time Frame: Up to 36 months ]Genotyping for leucine rich repeat kinase 2 (LRRK2), Glucocerebrosidase (GBA) (all cases) and Parkin, Phosphatase and tensin homolog-induced putative kinase 1 (PINK1)(onset<50years)
- Categorisation of subtypes of Parkinson's using cluster analysis [ Time Frame: At 4 years ]
Clustering of motor and non-motor features measured using Movement Disorder Society Unified Parkinson's disease rating scale (MDS-UPDRS), Montréal cognitive assessment (MoCA), Non-motor symptom Scale (NMSS), Scale for outcomes in Parkinson's autonomic (SCOPA-AUT), Olfaction testing using University of Pennsylvania Smell Identification Test (UPSIT) or Sniffin' sticks, and Leeds anxiety and depression scale (LADS).
This will use sequential factor analysis of the results of the above assessments, followed established methods, firstly exploratory factor analysis and secondly confirmatory factor analysis. Factor scores and other clinically important variables will then be combined to construct a single dataset for carrying out the cluster analysis. Hierarchical clustering will then be applied, and models with between 2 and 5 clusters will be described and compared.
- Proportion of cases with Parkinson's who have vascular comorbidity and risk factors [ Time Frame: At 4 years ]Prior history of vascular events, or calculated using Quantification of Risk version 2 (QRISK2) vascular risk score
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02881099
|Department of Neurology, Queen Elizabeth University Hospital (Co-ordinating Centre)|
|Glasgow, Scotland, United Kingdom, G51 4DT|
|Study Director:||Donald Grosset, BSc, MD||Queen Elizabeth University Hospital, Glasgow, UK|